Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting

ConferenceMCO-010Positive

AI Analysis

Summary

Nanoscope Therapeutics will present at the 2026 American Society of Retina Specialists Annual Scientific Meeting, including data on an optogenetic therapy trial in macular degeneration and 3-year follow-up data from the RESTORE Phase 2b/3 trial of MCO-010 for retinitis pigmentosa.

Clinical Trial Data

Phase

Phase 2b/3

Importance:5/10

Sentiment:

0.50

optogenetic therapymacular degenerationretinitis pigmentosaPhase 2b/3conference presentation3-year follow-up data

Related Companies

$ATALF $TRAX

Read the original article

Published by PR Newswire Biotech on July 10, 2026 1:00 PM

Read Original